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Abstract Overactivation of the sympatho-adrenergic
system is an essential mechanism providing short-term
adaptation to the stressful conditions of critical illnesses. In
the same way, the administration of exogenous catechola-
mines is mandatory to support the failing circulation in
acutely ill patients. In contrast to these short-term benefits,
prolonged adrenergic stress is detrimental to the cardio-
vascular system by initiating a series of adverse effects
triggering significant cardiotoxicity, whose pathophysio-
logical mechanisms are complex and only partially eluci-
dated. In addition to the development of myocardial
oxygen supply/demand imbalance induced by the sustained
activation of adrenergic receptors, catecholamines can
damage cardiomyocytes by fostering mitochondrial dys-
function, via two main mechanisms. The first one is cal-
cium overload, consecutive to b-adrenergic receptor-
mediated activation of protein kinase A and subsequent
phosphorylation of multiple Ca2?-cycling proteins. The
second one is oxidative stress, primarily related to the
transformation of catecholamines into ‘‘aminochromes,’’
which undergo redox cycling in mitochondria to generate
copious amounts of oxygen-derived free radicals. In turn,
calcium overload and oxidative stress promote mitochon-
drial permeability transition and cardiomyocyte cell death,
both via the apoptotic and necrotic pathways. Comparable
mechanisms of myocardial toxicity, including marked
oxidative stress and mitochondrial dysfunction, have been
reported with the use of cocaine, a common recreational
drug with potent sympathomimetic activity. The aim of the
current review is to present in detail the pathophysiological
processes underlying the development of catecholamine
and cocaine-induced cardiomyopathy, as such conditions
may be frequently encountered in the clinical practice of
cardiologists and ICU specialists.
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Introduction
Most critically ill patients disclose a hyperadrenergic state
as a primary adaptive response to the acute stress imposed
to their organism. In addition, exogenous catecholamines
represent the first-line therapeutic agents to improve car-
diovascular dysfunction in intensive care unit (ICU)
patients. Whereas a prompt surge of sympathetic stimula-
tion is essential for survival under conditions of acute
circulatory failure, prolonged exposure to elevated levels of
catecholamines may, by contrast, become maladaptive and
can result in significant adverse effects [1]. Of primary
concern, sympathetic overstimulation promotes cardiac
toxicity, whose detrimental consequences have been well
established in the field of chronic heart failure syndromes
[2]. With respect to acute illnesses, this issue has recently
begun to attract particular attention, with the publication of
several studies reporting adverse cardiovascular effects,
and possibly increased mortality, associated with cate-
cholamine administration [3–5]. The mechanisms respon-
sible for the cardiac toxicity of adrenergic agents remain
only partly defined, but recent findings have highlighted the
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crucial role played by altered redox status and mitochon-
drial dysfunction in such toxicity [6]. The purpose of the
present article is to review the current state of knowledge
on this topic. Besides catecholamines, a section will also be
dedicated to cocaine, since this frequently used recreational
drug also promotes significant cardiac toxicity, via mech-
anisms depending, in part, on its sympathomimetic actions.
Catecholamines
Major pharmacological aspects of catecholamines
Catecholamines, released from the adrenal medulla and
from the central and sympathetic nervous system, function
as hormones and neurotransmitters playing crucial regula-
tory roles in the cardiovascular system. Structurally, cate-
cholamines include a dihydroxybenzene ring (catechol)
and a nitrogen group (amine). They are generated from the
aminoacid L-tyrosine through successive hydroxylation,
decarboxylation and methylation steps resulting in the
sequential formation of dihydroxyphenylalanine (L-Dopa),
dopamine, norepinephrine (NE, noradrenaline) and epi-
nephrine (Epi, adrenaline) [6, 7] (Fig. 1). The pharmaco-
logical actions and the cell responses to catecholamines are
mediated by two major types (a and b) of G proteins-
coupled adrenergic receptors. The a-adrenoceptors are
further subdivided into a1 (a1A, a1B, a1D subtypes) and a2
(a2A, a2B and a2C subtypes) receptors, while the b-
adrenoceptors comprise the b1, b2 and b3 subtypes [8, 9].
The a1 receptors are coupled to pertussis-insensitive G
protein (Gq/11) to activate phospholipase C, promoting an
increase in cytosolic Ca2? ([Ca2?]i) via the formation of
diacylglycerol and inositol triphosphate [6]. In cardiac
myocytes, a1A and a1B adrenoceptors mediate positive
inotropic effects and hypertrophic responses, respectively,
whereas in vascular smooth muscle cells, a1D adrenocep-
tors elicit arterial vasoconstriction, notably in the coronary
arteries [6, 10]. The a2 receptors are coupled to inhibitory
G proteins (Gi and G0) and inhibit adenylyl cyclase sig-
naling. They are essentially expressed at the nerve
terminals from noradrenergic neurons, where they regulate
neurotransmitter release via an inhibitory presynaptic
feedback loop [6, 11]. The b1 and b2 receptors activate a
Gs-adenylyl cyclase-cAMP-protein kinase A (PKA) cas-
cade, leading to an increase in [Ca2?]i. In the heart, this
translates into positive inotropic, chronotropic, bathmo-
tropic and lusitropic effects, resulting in an increase in
heart rate, cardiac output, stroke work and cardiac relaxa-
tion (mainly mediated by b1 receptors) [6, 12]. In vascular
smooth muscle, both b1 and b2 receptors mediate relaxant
responses and vasodilation [13]. The b3 receptors,
expressed by cardiac myocytes, trigger a Gi–NO–cGMP
pathway, which produces a negative effect on cardiac
contractility [14]. Finally, in addition to a and b adreno-
ceptors, five types of dopaminergic receptors exist (D1–5).
D1 and D5 are coupled to Gs and activate adenylyl cyclase,
whereas D2–4 inhibit adenylyl cyclase via Gi signaling. In
the heart, only D1 and D4 are expressed, mediating some
inotropic actions [10, 15]. The affinity of catecholamines
for the different receptors is indicated in Table 1.
The pharmacological actions of catecholamines are
terminated by two major mechanisms, including reuptake
(both presynaptic and extraneuronal) and metabolism [6].
The later depends primarily on oxidative deamination by
neuronal mono-amine oxidase (MAO) to form dihydroxy-
phenylglycol, which is in turn O-methylated by extraneu-
ronal catechol-O-methyl-transferase (COMT) into
methoxhydroxyphenylglycol (MHPG). Catecholamines
may also be first O-methylated into metanephrine and
normetanephrine and secondarily deaminated into MHPG.
MHPG is oxidized in the liver by alcohol and aldehyde
dehydrogenases to form vanillylmandelic acid, the major
Fig. 1 Structure of the main catecholamines
Table 1 Affinity of the different adrenoceptors to endogenous and
synthetic catecholamines and sympathomimetic agents
a1 a2 b1 b2 b3 DR1–5
Adrenaline ??? ??? ???? ??? ? 0
Noradrenaline ???? ??? ??? ? ? 0
Dopamine ?? ? ???? ?? ? ????
Dobutamine ? ? ???? ?? 0 0
Isoproterenol – – ??? ??? ? 0
Phenylephrine ???? 0 0 0 0 0
Ephedrine ??? ??? ?? ?? ? 0
Endogenous catecholamines are represented by adrenaline, nor-
adrenaline and dopamine. Dobutamine and isoproterenol are synthetic
catecholamines with predominant b-adrenergic actions. Phenyleph-
rine is a sympathomimetic compound acting as a selective a1 agonist.
Ephedrine is a synthetic sympathomimetic agent with mild direct b-
agonist activity and with indirect a-agonist activity produced by
displacement of noradrenaline from nerve terminals. The table has
been drawn from [10, 85–87]
DR dopamine receptors
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end-product of norepinephrine and epinephrine metabo-
lism, which is excreted in the urine [7].
Catecholamine-induced cardiotoxicity
Increased levels of endogenous catecholamines occur
acutely to provide a short-term adaptation to stressful
conditions, which is known as the fight-or-fly response
[16]. Similarly, the exogenous administration of catechol-
amines is life-saving in clinical situations associated with
reduced cardiac output and/or hypotension [17]. In contrast
to these short-term benefits, sustained elevation of cate-
cholamines is detrimental to the cardiovascular system by
initiating significant cardiotoxicity [6], as observed in
chronic heart failure [18], pheochromocytoma [19], stress-
induced (‘‘takotsubo’’) cardiomyopathy [20] and during
prolonged therapy with high doses of exogenous cate-
cholamines [1]. According to this last condition, the
administration of the synthetic b-adrenoceptor agonist
isoproterenol to laboratory animals has been used for
decades as a well-recognized model of cardiac injury [21].
The morphological features of such injury, already
described by Richard M. Pearce in the early twentieth
century, reproduce many aspects of myocardial infarction
[22]. They include various degrees of cardiomyocyte
necrosis and apoptosis, myocardial infiltration with poly-
morphonuclear and mononuclear leukocytes, interstitial
edema, subendocardial and subepicardial hemorrhages, and
the progressive development of distinct foci of fibrosis over
time [6, 21]. On an ultrastructural viewpoint, the main
alterations of catecholamine-induced cardiac toxicity
comprise myofibrillar injury, mitochondrial swelling and
dilatation of the sarcoplasmic reticulum [6, 21].
Multiple mechanisms have been postulated to explain
the cardiotoxicity of catecholamines. The overstimulation
of catecholamine receptors enhances cardiac contractility
and heart rate, with secondary increase in myocardial
oxygen demand that may outweigh oxygen delivery, cre-
ating areas of ‘‘functional’’ hypoxia which can be exacer-
bated by vasoconstriction in the coronary macro- and
micro-circulation and which reduce the supply of high-
energy phosphates [6]. The later can be further aggravated
by metabolic changes, such as the stimulation of lipolysis
with deposition of neutral lipid droplets in cardiomyocytes
[23], resulting in an uncoupling of oxidative phosphoryla-
tion [24]. Changes in membrane permeability leading to
various electrolytic imbalances (hypokalemia, hypomag-
nesemia with reduced intracellular Mg2?) disturb multiple
cellular homeostatic processes fostering additional myo-
cardial toxicity [25].
Notwithstanding the aforementioned processes, there is
now substantial evidence to incriminate intracellular cal-
cium overload, oxidative stress and mitochondrial
dysfunction as the major mechanisms accounting for the
cardiotoxicity of catecholamines. A hallmark of sustained
catecholamine exposure is a significant rise in Ca2? both in
the cytosol ([Ca2?]i) and mitochondria ([Ca
2?]m) from
cardiomyocytes, whose importance in triggering myocardial
cell death has been identified more than 40 years ago by
Fleckenstein and colleagues [26, 27]. The ‘‘Fleckenstein
hypothesis’’ of Ca2?-mediated cardiotoxicity of catechola-
mines is nowadays described as the mitochondriocentric
signal transducer–effector (MSTE) pathway: Mitochondrial
Ca2? overload (signal) triggers mitochondrial oxidative
stress (transducer) and mitochondrial permeability transition
(effector), eventually leading to cell death via apoptotic and
necrotic pathways [28].
Myocardial [Ca2?]i and [Ca
2?]m build up in response to
b-adrenergic receptor-mediated activation of PKA, result-
ing in the downstream phosphorylation of multiple Ca2?-
cycling proteins, including sarcolemmal L-type Ca2?
channels, phospholamban and sarcoplasmic reticulum
ryanodine receptor Ca2? release channels (RyR2) [16].
PKA-dependent phosphorylation of troponin and myosin
binding protein C further participates to increase [Ca2?]i,
by reducing Ca2? affinity of myofilaments [6, 16]. Per-
sistent activation of b-adrenoceptors also promotes the
activation of Ca/calmodulin-dependent protein kinase II
(CaMKII), both via PKA-dependent and PKA-independent
mechanisms [29]. Activated CaMKII phosphorylates
multiple protein targets, which comprise voltage-gated
Ca2? channels, RyR2 Ca2? release channels and voltage-
gated Na? channels, with resulting increase in [Ca2?]i
[30]. Following the rise in [Ca2?]i, a progressive increase
in [Ca2?]m occurs, leading to a rapid change in the per-
meability of the inner mitochondrial membrane, followed
by swelling of the mitochondrial matrix, loss of respiratory
control and generation of reactive oxygen species (ROS)
which further exacerbates the Ca2?-induced mitochondrial
dysfunction [28].
The pathophysiological events triggered by elevated
[Ca2?]m are considerably amplified by the oxidative stress
that develops upon sustained exposure to high levels of
catecholamines, in connection with the following identified
mechanisms. First, MAO-dependent oxidative deamination
of catecholamines forms hydrogen peroxide (H2O2), which
may be converted to the highly reactive hydroxyl radical
(OH) through metal catalysis (Fenton chemistry) [6].
Secondly, activation of a1-adrenoceptors by catechola-
mines induces the activation of NADPH oxidase, with
ensuing generation of the superoxide anion radical (O2
-) in
cardiac myocytes [31]. Third, and most importantly, cate-
cholamines are readily oxidized into toxic compounds
termed ‘‘aminochromes’’ (due to their colored appearance
in solution) [24]. This process occurs spontaneously at a
low rate (autooxidation), but it is markedly accelerated in
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the presence of oxidants and free radicals such as O2
-,
redox metals (especially iron and copper) and by enzymatic
catalysis (notably by xanthine oxidase, myeloperoxidase
and cytochrome oxidase) [24, 32–34]. Catecholamine
oxidation is a two-electron process forming ortho-quinone
derivatives, followed by cyclization into leukoamino-
chromes which are further oxidized into aminochromes
[32], whose chemical structure is indicated in Fig. 2.
Aminochromes exert direct toxic effects on the coronary
arteries (vasoconstriction) and the myocardium, including
inhibition of oxidative phosphorylation and depression of
calcium binding, with the overall result to reduce con-
tractile force and to produce extensive necrotic damage, as
shown in both ex vivo [35–37] and in vivo [38] experi-
mental models. Besides their direct toxicity, aminochromes
also induce the formation of large amounts of ROS via
redox cycling processes occurring primarily in mitochon-
dria [39]. The first step of this cycle is the one-electron
reduction to aminochrome semiquinone in the presence of
NADH, catalyzed by complex I from the respiratory chain
[39, 40]. In the second step, the semiquinone immediately
regenerates the native aminochrome by auto-oxidation in
the presence of oxygen, releasing one molecule of O2
-
(Fig. 3). The cycle is then renewed, promoting an explo-
sive enhancement of O2
- generation, which, in turn, trig-
gers the further oxidation of catecholamines within their
respective aminochromes, whose concentrations is thereby
exponentially increasing [39].
When the formation of free radicals and oxidants out-
weighs the endogenous antioxidant capacities, a state of
oxidative stress develops with profound cytotoxic conse-
quences related to oxidative damage in lipids, proteins and
nucleic acids [41, 42]. The ‘‘oxidative stress theory’’ of
catecholamine cardiotoxicity is supported by a myriad of
studies showing considerable benefit of antioxidant thera-
pies, including melatonin [43], quercetin [44], ascorbic
acid [45] or N-acetylcysteine [46], to name only a few. It is
particularly noticeable that the oxidative stress elicited by
catecholamines, in conjunction with the marked [Ca2?]i
and [Ca2?]m overload, fosters the opening of the mito-
chondrial permeability transition pore (mPTP) in cardiac
myocytes, as recently well demonstrated in a model of
isoproterenol-induced cardiac injury [47]. Opening of the
mPTP promotes mitochondrial depolarization and cessa-
tion of oxygen transport. This triggers the secondary gen-
eration of free radicals, a process termed ‘‘ROS-induced
ROS release’’ (RIRR), which amplifies mitochondrial
oxidative stress and mPTP opening, leading to permeabi-
lization of the outer mitochondrial membrane and efflux of
pro-apoptotic molecules [48, 49]. Depending on the degree
of mPTP opening, cells may either recover (minimal
opening) or die by apoptosis (moderate opening) or
necrosis (massive, irreversible opening) [50, 51].
In summary, a sustained high level of catecholamine can
exert major toxic effects on the myocardium, leading to
morphological alterations similar to those produced by
myocardial infarction, including primarily cardiomyocyte
cell death and progressive focal myocardial fibrosis. Such
toxicity stems from a multiplicity of catecholamines’
actions on the heart, most significantly calcium overload,
oxidative stress and mitochondrial dysfunction, as illus-
trated in Fig. 4.
Cocaine
Pharmacological basis of cocaine effects
Cocaine (benzoylmethylecgonine), derived from the leaves
of Erythroxylon coca, is a commonly used illicit drug with
Fig. 2 Structure of
aminochromes formed from the
oxidation of catecholamines
Fig. 3 Formation of superoxide via redox cycling of aminochromes.
Aminochromes (ACR) are reduced to aminochrome semiquinones
(ACR-) in the presence of NADH by complex I in the inner
mitochondrial membrane. Auto-oxidation of ACR- back to ACR
induces the generation of the superoxide anion radical (O2
-). The
transfer of electrons is indicated by e-
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potent stimulant actions. It is generally used by nasal insuf-
flation or by inhalation (‘‘crack’’), reaching peak plasma
concentrations after 30–60 min or within seconds to min-
utes, respectively. Its serum half-life is about 60 min, being
rapidly cleared via tissue uptake and metabolism by plasma
and liver esterases into two major water-soluble active
metabolites, benzoylecgonine and ecgonine methylester,
excreted in the urine [52, 53]. The effects of cocaine are
related to the blockade of the presynaptic reuptake of
dopamine and norepinephrine, with resulting increase in
their concentration in the synaptic cleft and enhanced post-
synaptic transmission, as well as enhanced central sympa-
thetic outflow [54, 55]. The psychostimulant actions of
cocaine mainly result from enhanced dopamine neurotrans-
mission, whereas the cardiovascular effects of the drug are
related primarily to its sympathomimetic actions. In addi-
tion, cocaine also blocks the fast Na? channels in mem-
branes, reducing the phase 0 of the action-potential, thereby
inducing a local anesthetic effect [56, 57].
Cardiovascular consequences associated with cocaine
use
Cocaine use is associated with numerous acute and chronic
cardiovascular complications, which comprise chest pain,
hypertension, acute myocardial infarction, arrhythmias,
sudden death, aortic dissection, stroke (both ischemic and
hemorrhagic) and cardiomyopathy leading to chronic heart
failure [53, 55]. The primary mechanism of cocaine’s
cardiovascular toxicity relates to its marked sympathomi-
metic effect. Increased a1-adrenergic stimulation promotes
arterial vasoconstriction with subsequent elevation of
blood pressure and reduced microvascular blood flows,
whereas enhanced b-adrenergic stimulation increases heart
rate and cardiac contractility [54]. The vasoconstrictive
action of cocaine is further amplified by two additional
properties, namely inhibition of nitric oxide synthesis [58]
and increased formation of endothelin-1 [59] by the
endothelium. Furthermore, cocaine induces a prothrom-
botic state by activating platelets (via elevated P-selectin
expression, increased release of platelet factor 4, throm-
boglobulin, NAP-2 and CD40 ligand) [60] and coagulation
(via an increase in plasminogen-activator inhibitor, fibrin-
ogen and tissue factor, together with decreased expression
of tissue factor inhibitor, antithrombin and protein C) [56,
61, 62]. Over time, these various effects promote acceler-
ated atherosclerosis and endothelial dysfunction, which
further increase the risk of cardiovascular events (notably
myocardial infarction and ischemic stroke) in cocaine users
[55].
The significant increase in blood pressure due to a1-
adrenergic-dependent vasoconstriction is the major mech-
anism responsible for acute complications such as cerebral
hemorrhage and aortic dissection in cocaine users [53, 55].
The a1-mediated coronary vasoconstriction, together with
the b1-adrenergic-induced tachycardia and increased con-
tractility, leads to an imbalance between myocardial oxy-
gen demand and supply, triggering myocardial ischemia
and acute myocardial infarction [53, 55], the risk of which
being increased 24-fold in the 60 min following cocaine
use [63]. Importantly, coronary vasoconstriction may ini-
tially resolve when serum cocaine concentration decreases,
but may backslide after several hours due to the effects of
cocaine metabolites, producing recurrent, delayed
Fig. 4 Mechanisms of
catecholamine-induced
cardiotoxicity. The major
pathways of cardiotoxicity are
indicated with the black arrows
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myocardial ischemia [53, 55]. Coronary thrombus forma-
tion due to platelet activation is an additional factor that
may precipitate myocardial infarction [57]. Cocaine can
further promote major arrhythmias and sudden cardiac
death, both via its sympathomimetic effects (increased
ventricular irritability) and its blocking effects on Na?
channels, which prolongs QRS duration and QT interval
and favors the development of reentrant circuits, similarly
to class I antiarrhythmic agents [53, 55, 57].
In the long term, chronic use of cocaine may result in a
particular form of cardiomyopathy with various degrees of
systolic and diastolic dysfunction, cardiac hypertrophy and
dilatation, resulting in chronic heart failure [53, 55]. His-
tological characteristics include loss of myofibrils, multiple
foci of contraction band necrosis, fibrosis and interstitial
infiltrates with inflammatory cells [57, 64], which are
similar to the cardiac lesions described following sustained
catecholamine exposure (for instance, during pheochro-
mocytoma) [55]. In a limited number of cases, evidence of
inflammatory myocarditis has been noted, characterized by
perivascular eosinophilic infiltrates and absence of necro-
sis, attributed to an hypersensitivity reaction to cocaine
itself or any contaminants added to adulterate the drug,
such as amphetamine, sugars or talc [57].
Role of oxidative stress and mitochondrial dysfunction
in cocaine cardiotoxicity
Recent observations support a key role of myocardial oxi-
dative stress and mitochondrial dysfunction in the patho-
genesis of cocaine-induced cardiomyopathy [65–67]. Indeed,
substantial evidence of cardiac oxidative damage, including
depletion of antioxidants and lipid peroxidation, has been
obtained both in laboratory animals [65, 66, 68] and humans
[69, 70] exposed to cocaine. Underlying mechanisms include
(1) indirect, catecholamine-induced, oxidative stress, due to
formation of aminochromes and redox cycling compounds
(see above), (2) the activation of the O2
--generating enzymes
NADPH oxidase [65, 66, 71, 72] and xanthine oxidase [73],
(3) the induced formation of ROS by dysfunctional mito-
chondria [67, 73, 74] and (4) the generation of pro-oxidant
derivatives of cocaine metabolites [74, 75].
Activation of NADPH oxidase (Nox) by cocaine in
cardiac myocytes has been linked with an a1-adrenergic-G
protein-PKC-coupled mechanism, leading to phosphoryla-
tion of the p47phox cytosolic subunit of the enzyme [71].
The dependence on a1-adrenoceptor was notably demon-
strated by the abrogation of Nox activation in the heart of
cocaine-treated rats after administration of the a1 antago-
nist prazosin [71]. Fan and co-workers then demonstrated
that cocaine could also activate Nox in rat myocardium via
PKC-dependent but a1-independent upregulation of the
expression of Nox-2, one of the two Nox isoforms (with
Nox4) present in cardiac tissue [72]. The activation of Nox
appears to be a critical event for the propagation of ROS
generation in hearts exposed to cocaine, as supported by
Isabelle et al. [65]. These investigators found, in a model of
chronic cocaine administration to rats, that O2
- formed in
response to Nox activation induced the secondary activa-
tion of xanthine oxidase (XO) [76], leading to further O2
-
formation, which initiates a cycle of progressive amplifi-
cation of oxidative stress [65]. In addition, the intense
generation of O2
- by co-activation of Nox and XO targets
mitochondria to produce additional ROS via the RIRR
mechanims (ROS-induced ROS release) [49], contributing
to this amplification cycle [73].
An additional pathway of cocaine-mediated oxidative
stress which has received little attention may be related to
the formation of oxidative metabolites [75]. Besides the
major degradation pathway of cocaine by ester hydrolysis,
a minor N-oxidative pathway process also exists, in which
cocaine is demethylated to norcocaine, and then oxidized
to N-hydroxynorcocaine and norcocaine nitroxide [77, 78].
Evidence has been obtained that N-hydroxynorcocaine and
norcocaine nitroxide form a couple transferring electrons
from NADPH and generating O2
- during redox cycling, a
mechanism notably incriminated in the liver toxicity elic-
ited by cocaine [77, 79]. In addition to promote ROS for-
mation, these oxidized metabolites of cocaine have also
been associated with direct toxic effects on mitochondria,
by suppressing state 3 and 4 respiration, resulting in sup-
pression of ATP generation [74].
The primary target of cocaine-mediated oxidative stress
is the mitochondria, with various established consequences,
including formation of ROS (see above), impaired electron
transfer and suppression of ATP production [67, 73, 74], as
well as membrane permeabilization with release of cyto-
chrome C and subsequent cell death [80–82]. The mito-
chondrial impairment elicited by cocaine has been
particularly well addressed in a recent work by Vergeade
et al. [67]. In this study, the administration of cocaine for
seven consecutive days to rats resulted in significant left
ventricular dysfunction. At the cellular level, cocaine led to
an increase in oxygen consumption in cardiac fibers toge-
ther with increased ROS generation and decreased ATP
synthesis, indicative of an uncoupling of oxidative phos-
phorylation. The changes were selectively noted in the
interfibrillar fraction, but not the subsarcolemmal fraction
of mitochondria, pointing to differential susceptibility of
distinct mitochondrial fractions to pathological stimuli. Co-
treatment with cocaine and MitoQ, a mitochondrial-tar-
geted antioxidant [83, 84], suppressed these mitochondrial
abnormalities and completely prevented cardiac dysfunc-
tion, thereby providing strong support to the role of a
mitochondrial defect in cocaine-mediated cardiotoxicity
[67].
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Figure 5 summarizes the mechanisms involved in car-
diovascular toxicity associated with cocaine use. Besides
its considerable sympathomimetic effects resulting in cat-
echolamine-mediated adverse actions, cocaine also fosters
the generation of significant amounts of ROS within
cardiomyocytes, whose major consequence is mitochon-
drial dysfunction with subsequent activation of cell death
processes.
Conclusions
Although catecholamines are essential to support life in
conditions of acute cardiovascular failure, sustained
adrenergic stimulation exposes to the risk of significant
cardiotoxicity. In addition to the direct role of sustained
stimulation of adrenoceptors, catecholamines promote
profound mitochondrial dysfunction in cardiac myocytes
by inducing intracellular calcium overload and, most
importantly, by initiating mitochondrial oxidative stress
following their transformation into toxic aminochromes.
Mitochondria also play a central role in the cardiac toxicity
of cocaine, which acts, partly, through its sympathomi-
metic actions, but also through its ability to disturb redox
balance in cardiac myocytes. Clinicians should be aware of
these dangerous side effects in order to prevent the detri-
mental consequences of hyperadrenergic stress, notably by
a cautious use of exogenous catecholamines. Furthermore,
future studies should evaluate whether antioxidant mole-
cules efficacious in laboratory animals, such as the recently
developed mitochondrial-targeted antioxidants, can protect
the heart from the toxicity of catecholamines and cocaine
in the clinical setting.
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